Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313272 | 1.00 | PTGS1 (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL313183 | 0.83 | FOLH1 (0.36) | ENPEPFOLH1CHRM1AKR1A1CHRM3 | |
| SCHEMBL5961754 | 0.83 | FOLH1 (0.36) | ENPEPFOLH1CHRM1AKR1A1CHRM3 | |
| SCHEMBL3728136 | 0.81 | CHRM1 (0.33) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL19737260 | 0.79 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL20512314 | 0.79 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL17772932 | 0.77 | PTGS1 (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL7150005 | 0.77 | PTGS1 (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL11584178 | 0.77 | PTGS1 (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL8407151 | 0.77 | TDP1 (0.39) | MAPTSMN1; SMN2FOLH1CHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115317-A1 | GENE THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-3890772-B1 | BOTULINUM TOXIN FOR USE IN THE TREATMENT OF SYMPTOMS OF TRAUMATIC BRAIN INJURY | IPSEN BIOPHARM LTD (GB) | 2026-04-01 | — | — | EP | disclosed |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | IPSEN BIOPHARM LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| EP-4713004-A1 | TREATMENT OF A HEADACHE DISORDER WITH A BOTULINUM NEUROTOXIN A | Ipsen Biopharm Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4401759-B1 | MODIFIED BONT/A FOR USE IN THE TREATMENT OF CERVICAL DYSTONIA | IPSEN BIOPHARM LTD (GB) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694936-A1 | STEAP2 ANTIBODY DRUG CONJUGATES AND USES THEREOF | MedImmune, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545944-B2 | Method of detection | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20260021170-A1 | TREATMENT OF PAIN | IPSEN BIOPHARM LTD (GB) | 2026-01-22 | — | — | US | disclosed |
| US-20260014237-A1 | TREATMENT OF PAIN | IPSEN BIOPHARM LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4676545-A1 | SYNTHETIC PROMOTERS | Imperial College Innovations Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2002092784-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 | EMORY UNIVERSITY (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1247869-A1 | Process for the production of non-proteinogenic amino acids | Consortium für elektrochemische Industrie GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-6372889-B1 | USEFUL FOR MODULATING CELLULAR PROLIFERATION AND DIFFERENTIATION AND MAY BE USED FOR DIAGNOSTIC PURPOSES | ZYMOGENETICS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020042093-A1 | SECRETED PROTEINS ENCODED BY HUMAN CHROMOSOME 13 | ZYMOGENETICS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020012967-A1 | Insulin homolog polypeptide zins4 | ZYMOGENETICS, INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1141274-A2 | SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING THEM FOR THERAPY | ZymoGenetics, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6245529-B1 | NUCLEOTIDE SEQUENCES WHICH CODE UROGENITAL POLYPEPTIDES; FOR THE DIAGNOSIS AND TREATMENT OF REPRODUCTIVE DEFECTS | ZYMOGENETICS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6235708-B1 | Testis-specific cystatin-like protein cystatin T | ZYMOGENETICS, INC | 2001-05-22 | — | — | US | disclosed |
| WO-2000040716-A2 | SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING THEM FOR THERAPY | ZYMOGENETICS, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000031264-A2 | TESTIS-SPECIFIC CYSTATIN-LIKE PROTEIN CYSTATIN T | ZYMOGENETICS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021170-A1 | TREATMENT OF PAIN | CHRND, CHRNB2, CHRNA2 | PTGS1 1870/4885SLC7A11 1009/4885KDM4E 3914/4885 |
| US-20260014237-A1 | TREATMENT OF PAIN | CHRNB3, CHRNA3, CHRNA9 | PTGS1 1734/4885SLC7A11 4087/4885KDM4E 4643/4885 |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | PDXK, VIP, F13B | PTGS1 3031/4885SLC7A11 3102/4885KDM4E 3421/4885 |
| US-12545944-B2 | Method of detection | PHOSPHO1, NAAA, LIPA | PTGS1 4288/4885SLC7A11 2520/4885KDM4E 2178/4885 |
| US-20260115317-A1 | GENE THERAPY | CCL11, MPO, GSTA2 | PTGS1 87/4885SLC7A11 172/4885KDM4E 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.